S49 C-reactive protein as a biomarker for improved efficacy of lenzilumab in Covid-19 patients: results from the LIVE-AIR trial

Temesgen Z., Burger CD., Baker J., Polk C., Libertin CR., Kelley CF., Marconi VC., Orenstein R., Catterson VM., Aronstein WS., Durrant C., Chappell D., Ahmed O., Chappell G., Badley AD.

DOI

10.1136/thorax-2021-btsabstracts.55

Type

Conference paper

Publisher

BMJ Publishing Group Ltd and British Thoracic Society

Publication Date

11/2021

Permalink Original publication